Abstract: The invention relates to anthracycline derivative compounds for treating tumor diseases, and related methods, compositions, and kits.

Abstract: The invention relates to anthracycline derivative compounds for treating tumor diseases, and related methods, compositions, and kits.

Abstract: The invention relates to an antisense or siRNA oligonucleotide or conjugate with improved pharmacokinetic properties, methods of producing the same as well as the use of such compounds and conjugates, e.g. as pharmaceutical composition, a pharmaceutical kit, a medicament or a tool in biomedical research. The conjugates of the invention have the formula I being P-(L-S—S—Y—X)n, wherein P represents a natural, artificial and/or modified oligonucleotide, L represents a linker group attached to one or more nucleosides at any position within the oligonucleotides sequence; S represents sulfur; X represents a ligand; Y represents a spacer and n is an integer ranging from 1 to the oligonucleotide length of P.

Abstract: The invention relates to an antisense or siRNA oligonucleotide or conjugate with improved pharmacokinetic properties, methods of producing the same as well as the use of such compounds and conjugates, e.g. as pharmaceutical composition, a pharmaceutical kit, a medicament or a tool in biomedical research. The conjugates of the invention have the formula I being P-(L-S-S-Y-X)n, wherein P represents a natural, artificial and/or modified oligonucleotide, L represents a linker group attached to one or more nucleosides at any position within the oligonucleotides sequence; S represents sulfur; X represents a ligand; Y represents a spacer and n is an integer ranging from 1 to the oligonucleotide length of P.

Abstract: The invention relates to compounds of the general formula (I) in which R1 is a hydrogen atom, a hydroxy or methoxy group, a halogen atom, or an NO2 group; R2 is a hydrogen atom, a hydroxy or methoxy group, or an acyl or aroyl group; R3 is hydrogen, trifluoroacetyl (C(?O)CF3), or p-nitrobenzoyl (C(?O)PhNO2), and in each case the wavy line represents both possible configurations of —OR3 relative to the skeleton; Y is [C(?O)], [C(?N)—OH], [CH—OH], or [CH—NR5R6] in the two possible stereoisomer arrangements, wherein R5 and R6 either each represent a hydrogen atom or a hydrogen atom and a trifluoroacetyl group (TFA); X=O, S, or NR, in which R=hydrogen or a C1 to C4 alkyl group; and R4 is an unbranched or branched alkyl or heteroalkyl chain with a chain length of 1 to 19 elements, maximally 6 heteroatoms (O, N, S) being separated from one another in any combination by at least two carbon atoms.